SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Chidamide-Nivolumab Combo Cuts Melanoma Progression Risk 27% in Phase 3 Trial

The combination showed a 0.73 hazard ratio for progression-free survival versus nivolumab alone in a global Phase 3 trial.

Related stories